AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Beyfortus (nirsevimab by Quarter
Beyfortus (nirsevimab — direct product sales) — US YoY (%) (%)
AstraZeneca Beyfortus (nirsevimab: -49.0% in Q2 2026.
Latest, Q2 2026
-49.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
8 quarters
Since Q2 2023
Sources
8
Documents cited below
Where the Q2 2026 figure comes from
“|| Beyfortus | | 47 | | ( 52 ) | | ( 52 ) | | 38 | | ( 49 ) | | - | | - | | - | | 8 | | ( 66 ) | | ( 67 ) | | 1 | | 34 | | 58”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — US YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -49.0% | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -18.0% | -27.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -44.0% | -105.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -63.0% | – | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 9.0% | – | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 61.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 0.0% | – | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 0.0% | – | Form 6-K FY2023Q2 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab (%), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-beyfortus-us-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.